Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
This article examines the week-by-week progression of weight loss with retatrutide, the impact of dose escalation on the timeline, and what the clinical data suggest about when individuals can expect to see results
Results from the TRIUMPH-4 trial, published in December 2025, showed participants with obesity and knee osteoarthritis taking retatrutide 12mg lost an average of 28.7% of their body weight at 68 weeks
The one bright spot in the clinical data is safety
Stock up on bland foods before the 1mg to 1.7mg transition
Insulin resistance can also affect ovarian function, leading to the formation of cysts and irregular ovulation
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) not yet approved by the MHRA or EMA as of 2025
US$ 23.87
US$ 24.91
US$ 20.21
US$ 24.42
US$ 29.58
